Side effects and complications of injection laryngoplasty for treatment of congenital type 1 laryngeal clefts

被引:7
作者
Ramazani, F. [1 ]
Isaac, A. [1 ]
Johannsen, W. [1 ]
El-Hakim, H. [1 ]
机构
[1] Univ Alberta, Stollery Childrens Hosp, Dept Surg, Div Otolaryngol Head & Neck Surg,Div Pediat Surg, Edmonton, AB, Canada
关键词
Injection augmentation; Type 1 laryngeal cleft; Injection laryngoplasty; Complications; Stridor; Pediatric; AUGMENTATION; MANAGEMENT; DIAGNOSIS; OUTCOMES; CHILDREN; FILLER;
D O I
10.1016/j.ijporl.2020.109886
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Introduction: Injection laryngoplasty (IL) is a brief, minimally invasive procedure involving injection of agents to augment the interarytenoid space. It was initially described as a diagnostic and temporizing measure for management of type one laryngeal clefts (LC1) and associated swallowing dysfunction (SwD), but more gradually it is being proposed as a definitive treatment modality. However, the morbidity of this treatment for LC1 remains under-investigated. This study sought to determine the morbidities associated with IL as a treatment modality for LC1 and associated SwD. Method: Single centre retrospective review of a prospective surgical database of one Pediatric Otolaryngologist at a tertiary care center. Participants included pediatric patients with an endoscopic diagnosis of LC1, treated with IL between 2000 and 2018-excluding those with concurrent upper airway anomalies. Patient charts were reviewed for demographic information, immediate post-op complications (within the first 14 days following IL), and subsequent management. Results: Out of 85 consecutive, eligible patients, 12 were excluded (5 subglottic stenosis, 6 laryngomalacia, and one tracheomalacia). Of the 73 included patients, 42 were male and 31 females. The median age at IL was 29 months (range 1-132, interquartile range of 38 months). All IL procedures in this study utilized hyaluronic acid derivatives. From this series, 13 patients experienced post-operative complications. The complications encountered were respiratory distress (N = 5), croup-like cough (N = 6), and stridor (N = 6). These complications were either self-limiting (N= 9), managed by systemic or inhaled steroids (N = 4), or admitted to hospital for monitoring (N=3). One case (augmented with dextranomer and hyaluronic acid) required intubation, repeat endoscopy, and drainage of seroma. Conclusion: IL was followed by respiratory morbidity in nearly two in ten of this series of consecutive patients. All the morbidities occurred in association with one injection product. Parents should be counselled appropriately about potential morbidities associated with this procedure.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] Retroprosthetic membrane formation in Boston keratoprosthesis type 1: Incidence, predisposing factors, complications, and treatment
    Mina, M.
    Harissi-Dagher, M.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2024, 47 (02):
  • [32] Retroprosthetic Membrane Formation in Boston Keratoprosthesis Type 1: Incidence, Predisposing Factors, Complications, and Treatment
    Khair, Diana
    Daoud, Roy
    Harissi-Dagher, Mona
    CORNEA, 2022, 41 (06) : 751 - 756
  • [33] Treatment of strabismus and nystagmus with botulinum toxin type A - An evaluation of effects and complications
    Lennerstrand, G
    Nordbo, OA
    Tian, S
    Eriksson-Derouet, B
    Ali, T
    ACTA OPHTHALMOLOGICA SCANDINAVICA, 1998, 76 (01): : 27 - 37
  • [34] The association between vascular complications during pregnancy in women with Type 1 diabetes and congenital malformations
    Samii, L.
    Kallas-Koeman, M.
    Donovan, L. E.
    Lodha, A.
    Crawford, S.
    Butalia, S.
    DIABETIC MEDICINE, 2019, 36 (02) : 237 - 242
  • [35] Selumetinib in the Treatment of Symptomatic Intractable Plexiform Neurofibromas in Neurofibromatosis Type 1: A Prospective Case Series with Emphasis on Side Effects
    Baldo, Francesco
    Grasso, Antonio Giacomo
    Wiel, Luisa Cortellazzo
    Maestro, Alessandra
    Trojniak, Marta Paulina
    Murru, Flora Maria
    Basso, Luca
    Magnolato, Andrea
    Bruno, Irene
    Barbi, Egidio
    PEDIATRIC DRUGS, 2020, 22 (04) : 417 - 423
  • [36] Factors associated with gastrointestinal side effects after liraglutide treatment for type 2 diabetes
    Wu, Hao
    Lu, Zongshi
    Chen, Runyao
    Cai, Quanfang
    Wang, Miaomiao
    Zhang, Liting
    Zhu, Zhiming
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [37] Azathioprine treatment in inflammatory bowel disease patients: type and time of onset of side effects
    Avallone, E. V.
    Pica, R.
    Cassieri, C.
    Zippi, M.
    Paoluzi, P.
    Vernia, P.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2014, 18 (02) : 165 - 170
  • [38] Treatment with insulin analogs and prevalence of cardiovascular complications in patients with type 1 diabetes
    Hasslacher, Christoph
    Bermejo, Justo Lorenzo
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2017, 8 (11) : 149 - 157
  • [39] Comparison of continuous subcutaneous insulin infusion treatment and multiple daily injection treatment on the progression of diabetic complications in Japanese patients with juvenile-onset type 1 diabetes mellitus
    Masuda, Takafumi
    Katakami, Naoto
    Taya, Naohiro
    Miyashita, Kazuyuki
    Takahara, Mitsuyoshi
    Kato, Ken
    Kuroda, Akio
    Matsuhisa, Munehide
    Shimomura, Iichiro
    JOURNAL OF DIABETES INVESTIGATION, 2022, 13 (09) : 1528 - 1532
  • [40] Congenital Type 1C Choledochal Cyst: Clinical Presentation and Surgical Treatment
    Nseir, Mazen
    Aughsteen, Adib A.
    Mahmood, Mahmood F.
    Al-Khayat, Muzahim
    Hawamdeh, Hasan M.
    Bani-Hani, Kamal A.
    INDIAN JOURNAL OF SURGERY, 2013, 75 : S220 - S223